Genetown
Filter News
Found 85,620 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD
3/22/2023
Pressure BioSciences, Inc. today announced the execution and launch of a manufacturing and distribution agreement (the "Agreement").
-
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
3/22/2023
Ancora Heart, Inc today announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
3/22/2023
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period and full year ended December 31, 2022.
-
DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting
3/22/2023
DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/22/2023
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
-
Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer
3/22/2023
Remix Therapeutics today announced the appointment of Robert Gagnon as Chief Financial Officer.
-
Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression
3/22/2023
Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.
-
Sage Therapeutics to Present at the Stifel 2023 CNS Days
3/22/2023
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET.
-
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
3/22/2023
Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.
-
Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden
3/22/2023
Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.
-
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock - March 22, 2023
3/22/2023
Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.
-
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
3/22/2023
Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA®.
-
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
3/22/2023
Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported financial results for the full year ended December 31, 2022, and provided a corporate update.
-
Caraway Therapeutics to Present at Stifel CNS Days
3/22/2023
Caraway Therapeutics today announced that the Company will be participating in the Stifel CNS Days event on March 29, 2023.
-
Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
3/21/2023
Lumicell, Inc. today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been submitted to the U.S. Food and Drug Administration (FDA).
-
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
3/21/2023
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.
-
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
3/21/2023
Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia.
-
Mispro Biotech Services Celebrates 20th Anniversary with a Fresh Look: Company Unveils Brand Refresh to Mark Two Decades of Innovation and Growth
3/21/2023
Mispro Biotech Services, North America's pioneering contract vivarium organization, is proud to announce its 20th anniversary and brand refresh to commemorate the occasion.
-
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
3/21/2023
Decibel Therapeutics today announced the appointment of Matthew Kapusta to its Board of Directors.